Checkpoints and cancer
Just as decreased licensing is shown here to promote genetic instability and cancer, excessive licensing in the same cell cycle seems to have similar effects. For example, repeated licensing in the same cell cycle (re-replication) is promoted by an excess of the licensing factor Cdt1 and its partner Cdc6 or by a decrease in an inhibitor of licensing, geminin 5, 6 . Excess Cdt1 in mice promotes cancer 7 , whereas excess Cdt1 or Cdc6 in human cancer is correlated with excess genetic instability and a poorer prognosis 8 . In several studies, the genetic instability arising from deregulation of replication licensing activates checkpoint pathways that stop cell proliferation and eventually lead to cell death (Fig. 1b) . For example, re-replication activates both the S-G2 checkpoint and the p53 tumor suppressor, and cancers arising in the context of Cdt1 overexpression often have mutations in the gene encoding p53 (reviewed in refs. 5, 6) . Conversely, inadequate licensing imposed experimentally by overexpression of geminin or knockdown of Orc2 leads to a G1 arrest that, at least in one case, is mediated by the stabilization of the cyclin-dependent kinase 2 (Cdk2) inhibitor p27 (Fig. 1c) 9, 10 . Thus, one point of interest will be whether Mcm4 Chaos3/Chaos3 cells activate checkpoint pathways and whether mutations in p53, or activated degradation of p27, are important for the development of mammary carcinomas in Mcm4 Chaos3/Chaos3 mice.
Although much attention has been paid to germline and somatic mutations in DNA damage repair genes that predispose to cancer or promote cancer progression, the current study highlights the importance of screening for mutations in genes involved in DNA replication. Any derangement in the proteins that maintain the high fidelity of replication and the close link between replication, cell cycle and cell division is expected to lead to genomic instability. Homozygous null mutations are unlikely to be seen in cancer cells or in a person predisposed to cancer, but hypomorphic mutations similar to Chaos3 are entirely possible. One hopes that the genes selected for screening in cancer genome projects include the complete assortment of genes involved in DNA replication. Decreases in the activity of a gene or protein can also arise from epigenetic and post-transcriptional mechanisms. For example, overexpression of cyclins E, D and A has been often described in cancers, and these cyclins (paired with their relevant CDKs) are known to phosphorylate components of the prereplicative complex and prevent the loading of . Elevated levels of these cyclins (or decreased levels of CDK inhibitors like p27) could promote cancer development or progression through decreased origin licensing and genomic instability, similar to observations in Mcm4 Chaos3/Chaos3 mice.
Telomeres, p21 and the cancer-aging hypothesis
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Telomere dysfunction suppresses cancer through the p53 tumor suppressor pathway but also contributes to aging. A new study suggests that these effects of dysfunctional telomeres may be separable, such that aging-but not cancer suppression-depends on the p21 cell cycle inhibitor. The 'cancer-aging hypothesis' proposes that neoplastic disease and the age-induced degeneration of many organs are closely linked by the failure or success of tumor suppressor mechanisms such as cellular senescence. For example, activation of the p16 tumor suppressor in selfrenewing compartments such as hematopoietic stem cells (HSCs) seems to contribute to aging 1 , yet inactivation of p16 is an early step in the formation of many cancers 2 . An important prediction of the cancer-aging hypothesis is that certain well-intended efforts to prevent aging (growth hormone replacement to retard muscle loss, for example) may accelerate cancer formation, and vice versa. Work from Aaheli Roy Choudhury and colleagues on page 99 of this issue 3 is therefore surprising in that it shows that deficiency of the p53 effector p21 extends longevity and rescues stem cell function in mice with dysfunctional telomeres, without sacrificing tumor suppression.
Taking the bad with the good Strong evidence from disparate systems suggests that telomere dysfunction is a critical tumor suppressor mechanism in humans 4 . In the absence of telomerase activity, persistent proliferation leads to telomere shortening and dysfunction, which in turn induces replicative senescence. Most human cancers have to solve the problem of telomere shortening, usually by reactivating telomerase activity. Evidence that telomere dysfunction also contributes to human aging is accumulating. For example, mice genetically engineered to harbor short telomeres show premature aging 5 , and evidence of telomere NATURE GENETICS | VOLUME 39 | NUMBER 1 | JANUARY 2007 11 dysfunction can be detected in primate skin during the physiological aging process 6 . Moreover, humans with mutations that compromise the telomerase RNA-protein holoenzyme complex develop premature bone marrow failure and a shortened lifespan 7, 8 . This dual role in preventing cancer and causing aging has made telomere-based replicative senescence a prominent component of the cancer-aging hypothesis. The p53 tumor suppressor is a major determinant of the organismal response to telomere dysfunction (Fig. 1) . Previous work has shown that telomere dysfunction is sensed in a manner similar to DNA double-strand breaks, with activation of p53 effecting either senescence or apoptosis 4 . In agreement with this model, p53 deficiency rescues many of the phenotypic consequences of telomere dysfunction such as impaired fertility and germ cell apoptosis in mice with pathologically shortened telomeres 9 . Despite these impressive phenotypic effects of telomere dysfunction, animals with shorttelomeres that also lack p53 do not live longer than animals with short telomeres and intact p53. On the contrary, such p53-deficient, shorttelomere mice are highly prone to tumors, suggesting the provocative possibility that either aging or cancer is the outcome of telomere dysfunction, depending on p53 function. p21 makes a difference Given this background, Choudhury et al. 3 examined the effect of p21 deficiency in mice with dysfunctional telomeres. p21 is an inhibitor of cyclin-dependent kinases that is transcriptionally activated by p53 to induce cell-cycle arrest. Although the ability of p53 to induce cellular senescence seems to be crucial to its tumor suppressor activity, several lines of evidence suggest that p21 is not a critical effector of the tumorsuppressive effects of p53. For example, few, if any, genetic lesions specifically and reproducibly targeting p21 have been reported in human cancers, and mice with germline deficiency of p21 are only modestly prone to tumors (for example, see Figure 1 of Choudhury et al. 3 ). In fact, others 10 have reported that germline p21 deficiency increases the sensitivity of mice to ionizing radiation but delays the onset of cancer. In accord with this previous work, Choudhury et al. showed that in contrast to p53 deficiency, inactivation of p21 in animals with telomere dysfunction dramatically extended survival. Together, these results suggest that the principal role of p21 is not in tumor suppression but rather in the evolutionarily oldest task of p53: mediating the cellular response to DNA damage and other stresses (Fig. 1) . Surprisingly, this activity of p53, through p21, seems to promote aging, in response to the persistent signal that results from telomere dysfunction.
Focus on stem cell function
To understand the physiological basis of the effect on lifespan, Choudhury et al. undertook a detailed study of specific stem cell compartments in aging mice with and without telomere dysfunction. Whereas the number of HSCs did not decline with aging in wild-type mice, the authors noted reduced number and function of HSCs in mice with telomere dysfunction, in agreement with previous studies 11, 12 . These results are further informed by a recent publication 13 showing that increased p53 expression in HSCs impairs their function with aging, indicating that p53 activation per se compromises the HSC compartment. Consistent with its effect on lifespan, p21 deficiency attenuated the effects of pathogenic telomere shortening, resulting in improved HSC number and function. Similar rescue was suggested in the intestinal stem cell compartment, where p21 deficiency largely rescued the proliferative defects and intestinal epithelial atrophy associated with telomere dysfunction. These data suggest the intriguing possibility that p21 promotes aging in the context of telomere dysfunction by impairing stem cell function. The notion that p21 exerts this age-promoting role as part of a DNA damage and stressresistance response that is not required for tumor suppression is in agreement with recent experiments in mice with conditionally activatable p53 that similarly dissociated p53-mediated tumor suppression and stress response 14 . However, the effects of p21 can be highly beneficial in some settings in which transient growth arrest permits optimal DNA repair and cellular survival. For example, p21 seems to be critical in animal survival after exposure to ionizing radiation 10 and in maintenance of the HSC compartment after transient myelotoxic stress 15 . Perhaps the effect of p21 expression on stem cell function and aging depends on the nature of the stimulus leading to its induction (Fig. 1) . In this model, p21 expression after a transient stress (like a dose of ionizing radiation) would protect stem cells, and therefore oppose aging, whereas p21 may compromise stem cell function in the setting of a persistent stress (as with telomere dysfunction).
In summary, this study suggests that one can, with regard to the cancer-aging hypothesis, have one's cake and eat it too, at least for a little while. That is, inhibition of p21 seems to protect against the age-promoting effects of telomere dysfunction on stem cells, without an attendant rise in tumorigenesis. Presumably, this is possible because p53 is a very good tumor suppressor that can efficiently induce apoptosis or senescence, even in the absence of p21. Assuming that telomere shortening and/or p53 activation contribute to aspects of stem cell compromise in humans, one hopes a similar separation of p53's age-promoting and tumor-suppressive activities can be achieved in humans. With the preclinical development of pharmacological modulators of p53 function, we expect this question will soon move from the academic to the clinical setting.
